Estonia: Medical Cannabis Market Overview 2025

In Estonia, medical cannabis is not formally legalised under a dedicated regulatory framework but can be accessed as an unlicensed medicine through a special permit process administered by the State Agency of Medicines (SAM).

This system allows for case-by-case patient access when all other authorised treatment options have been exhausted, making Estonia’s programme one of the most restrictive and bureaucratic in Europe.

The process is designed for exceptional medical necessity and has resulted in extremely low patient numbers and no commercial medical cannabis market. There are no licensed domestic cultivators or manufacturers, and all medical cannabis products are imported on a per-patient basis following SAM approval.

Medical cannabis in Estonia is regulated under the Medicinal Products Act and the Narcotic Drugs and Psychotropic Substances Act, which classify cannabis as a controlled narcotic substance.

While there is no general framework for medical cannabis use, the SAM can authorise the use of unlicensed medical cannabis products in special cases, following a detailed application process initiated by a prescribing specialist.

Special Permit Process:

This multilayered process typically takes several weeks to months and involves significant administrative hurdles, particularly as many pharmacies and distributors lack experience handling cannabis-based products.

Licensing & Oversight:

Manufacturing: Prohibited.

Oversight authority: State Agency of Medicines (SAM)

Import and wholesale: Restricted to entities licensed to handle narcotic and psychotropic substances

Cultivation: Prohibited

Who Can Prescribe? Only specialist doctors (such as oncologists, neurologists, or pain management physicians) can initiate an application for medical cannabis treatment. General practitioners are not authorised to prescribe cannabis.

Prescribing Requirements:

Dispensation:

Reimbursement: There is no public reimbursement for medical cannabis in Estonia. All treatment costs must be paid out-of-pocket by the patient.

Due to the complex access procedures and lack of streamlined supply, Estonia’s medical cannabis market remains functionally inactive, with fewer than a dozen patients reportedly accessing cannabis-based medicines annually.

Estonia’s medical cannabis access model is among the most conservative in Europe, reflecting the country’s historically cautious stance toward controlled substances.

For the market to develop beyond isolated patient cases, Estonia would need to:

Until such reforms occur, Estonia’s medical cannabis landscape will remain limited to individual exemptions with no commercial infrastructure or measurable patient base.

Get granular market sizing forecasts, patient population data, and competitive intelligence across 31 European markets. Trusted by investors, operators, and regulators across the continent.